Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

Exclusion Criteria

• •4. Measurable disease, as defined as lesions that can accurately be measured in at least one dimension (longest diameter to be measured) according to Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) at least 2 cm with conventional techniques or at least 1 cm with spiral computed tomography.
• •5. Child-Pugh Score A.
• •6. Age ≥ 18 years.
• •7. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-2.
• •8. Absolute neutrophil count ≥ 1,500 cells/mm3.
• •9. Platelet count ≥ 75,000 cells/mm3.
• •10. Total bilirubin ≤ 3.0 mg/dl.
• •11. Hemoglobin ≥ 8.5 g/dl.
• •12. AST and ALT ≤ 5.0 times upper limit of normal.
• •13. D-dimer ≤ 3 times upper limit of normal.
• •14. INR ≤ 1.8 (therapeutic anticoagulation allowed as long as medically indicated.
• •1. History of bleeding diathesis or coagulopathy.
• •2. Symptomatic or clinically active brain metastases.
• •3. Major surgery within previous 4 weeks.
• •4. History of thromboembolic events (including both pulmonary embolisms and deep vein thrombosis); central venous catheter-related thrombosis \> 6 months prior is allowed.
• •5. Prior adjuvant therapy with sorafenib or other Raf/MEK/RAS or VEGFR inhibitors. Prior adjuvant therapy is allowed provided it was completed \> 6 months ago and there is documented recurrence of hepatocellular carcinoma.